2024 Volume 36 Issue 2 Pages 93-101
Objective: To elucidate the efficacy and safety of an adjuvanted herpes zoster-subunit vaccine（HZ/su）in RA patients treated with Janus kinase inhibitors（JAKis）in our institution.
Methods: We conducted a retrospective analysis of RA patients receiving treatment with JAKis, vaccinated with at least one dose of HZ/su in our hospital between April 2020 and December 2021.
Results: Sixty-nine RA patients treated with JAKis were enrolled（tofacitinib, n=3; baricitinib, n=27; peficitinib, n=6; upadacitinib, n=29; filgotinib, n=4）. The mean age was 67 years, 62 patients（89.9%）were aged ≥ 50 years, and 75.4% were female. Five patients（7.2%）had a history of HZ. Fifty-one patients（73.9%）had received two doses of HZ/su. Two patients（2.9%; 4.1/100 patient-years; nonmorbidity rate 97.1%; no disseminated HZ）had HZ reactivation after two doses of HZ/su. Both were aged >75 years. No severe adverse events or recurrence of RA disease activity after receiving HZ/su were reported.
Conclusions: HZ morbidity was lower in RA patients treated with JAKis receiving HZ/su in our institution compared with that previously reported in Asian RA patients treated with JAKis. Our results suggest that HZ/su could be safe and may be effective in preventing HZ reactivation in Asian RA patients receiving JAKi treatment. Extra attention should be paid to the possibility of HZ in elderly and immunosuppressed patients.
